<scp>FXYD3</scp> Is Frequently Expressed in Pancreatic Ductal Adenocarcinoma but Does Not Predict Survival
Immunohistochemical FXYD3 expression does not predict survival in chemo-naive PDAC patients, but is associated with late-stage disease. The high rate of FXYD3 overexpression warrants therapeutic evaluation.
Authors
- Jaswinder Singh Samra (ORCID: https://orcid.org/0000-0001-6664-7147)
- John Turchini (ORCID: https://orcid.org/0000-0003-4281-7134)
- H Rasmussen (ORCID: https://orcid.org/0000-0003-2409-4083)
- Anthony James Gill (ORCID: https://orcid.org/0000-0002-9447-1967)
- Sooin Byeon
- Anubhav Mittal (ORCID: https://orcid.org/0000-0003-3960-2968)
- Rachel Teh (ORCID: https://orcid.org/0000-0003-1396-2295)
- Sumit Sahni (ORCID: https://orcid.org/0000-0002-2900-8845)
- Nathalie B. Rasko
- Christopher B. Nahm (ORCID: https://orcid.org/0000-0003-0888-4499)
Institutions
- The University of Sydney (AU)
- Royal North Shore Hospital (AU)
- Macquarie University (AU)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1002/cam4.70500
- Citations
- 1
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- NSW Health Pathology